focus -WSS

focus

author：knowledge 2025-10-01 02:15:12 - browse：5714

Matts Take Column Illustration — Molly Ferguson for STAT

The news that the weight loss drug Wegovy reduced the risk of heart attacks and strokes in overweight volunteers opens up the door to vastly expanded use of the drug and medicines like it, known as GLP-1 medicines.

That could have a big, positive impact on public health, and it will very likely swell the coffers of the pharmaceutical companies that make these medicines, including Wegovy’s maker, Novo Nordisk, and Eli Lilly, now the most valuable drug company in history thanks largely to hopes for its GLP-1, Mounjaro. These are medicines that could save lives, make money, and perhaps reshape our culture. But they are also, we are learning, not without risk.

So what’s next?

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Heart attack and stroke risk calculators need revising
Next article： Thermo Fisher plant for manufacturing gene therapies to expand

explore

hotspot

WSS

Medical devices makers are asking for forgiveness, not permission

Readout LOUD podcast, live from the STAT Breakthrough Summit East

Case for ALS therapy Nurown relies on ‘deficient’ data, FDA finds

Readout LOUD podcast, live from the STAT Breakthrough Summit East

Lasker Awards 2023: Winners in biomedical research

Readout LOUD podcast: possible new ALS drug, artificial wombs

leisure time

focus

focus

Heart attack and stroke risk calculators need revising

Second xenotransplant done with gene

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Diabetes management: Digital health tools fall short, study says

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Ukraine and a new approach to mental health in war

Supreme Court strikes down use of affirmative action

Case for ALS therapy Nurown relies on ‘deficient’ data, FDA finds

Jerome Adams on the need for new antivirals for Covid

EpiPen alternative approval delay highlights citizen petition issue

Wikipedia

Asbestos ban is immediate, but health effects will linger for decades

Ukraine and a new approach to mental health in war

Novo Nordisk to buy Cardior, building up pipeline of heart drugs

Thermo Fisher plant for manufacturing gene therapies to expand

CDC advisers recommend seasonal use of Pfizer RSV shot

Pfizer, Moderna say biotech, pharma drug development is a sprint

focus

explore

hotspot

hotspot